MedTrace Logo

AK-R215 Pharmacokinetic Study Phase I

NCT03321318 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2017-10-25

No results posted yet for this study

Summary

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of AK-R215

Conditions

  • Healthy

Interventions

DRUG

AK-R215

Investigational product is prescribed to all ofrandomized subjects

DRUG

Bazedoxifene 20 mg

Investigational product is prescribed to all of randomized subjects

DRUG

Cholecalciferol 800IU

Investigational product is prescribed to all of randomized subjects

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-13
Primary Completion
2017-09-18
Completion
2018-01-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03321318 on ClinicalTrials.gov